Oncoinvent ASA
Clinical-stage biotech developing radiopharmaceutical therapies for peritoneal cancers.
OCIN | Euronext Growth
Overview
Corporate Details
- ISIN(s):
- NO0010779341 (+1 more)
- LEI:
- 54930076H5GUZRMSNR39
- Country:
- Norway
- Address:
- Gullhaugveien 7, 0484 Oslo
- Website:
- https://www.oncoinvent.com/
- Sector:
- Manufacturing
Description
Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies for cancer. The company's core focus is on direct alpha therapy, a technology platform designed to deliver potent, short-range radiation directly to cancerous tumors. Its lead product candidate, Radspherin®, is composed of inorganic microparticles that carry the alpha-emitting radionuclide Radium-224. This formulation is engineered for regional retention and slow degradation, enabling a high radiation dose to be administered within the peritoneal cavity while minimizing systemic exposure. Oncoinvent's clinical programs are primarily investigating the use of Radspherin® for treating metastatic cancers in the peritoneal cavity, including ovarian and colorectal cancer.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-04-28 06:05 |
Oncoinvent ASA: Invitation to Presentation of Q1 2025 company update
|
English | 3.3 KB | ||
| 2025-04-28 06:00 |
Oncoinvent Reports updated 18-Month Data from Phase 1 Ovarian Cancer Trial with…
|
English | 152.8 KB | ||
| 2025-04-28 06:00 |
Oncoinvent Reports updated 18-Month Data from Phase 1 Ovarian Cancer Trial with…
|
English | 5.3 KB | ||
| 2025-04-28 05:45 |
Financial calendar
|
English | 607 bytes | ||
| 2025-03-25 06:00 |
Oncoinvent ASA Announces Positive Safety Review of Lead-In Cohort, Advances to …
|
English | 3.8 KB | ||
| 2025-03-05 09:57 |
Oncoinvent ASA: Mandatory notification of trade
|
English | 1.6 KB | ||
| 2025-02-27 06:30 |
Oncoinvent ASA: Fourth Quarter 2024 Update and Results
|
English | 742.2 KB | ||
| 2025-02-27 06:30 |
Oncoinvent ASA: Fourth Quarter 2024 Update and Results
|
English | 4.4 KB | ||
| 2025-02-27 05:54 |
Oncoinvent ASA reports completed inclusion in the initial safety lead-in cohort…
|
English | 4.1 KB | ||
| 2025-02-20 06:42 |
Oncoinvent ASA: Invitation to Result Presentation Q4 2024
|
English | 3.0 KB | ||
| 2025-02-19 06:45 |
Oncoinvent ASA to present at various conferences
|
English | 2.9 KB | ||
| 2025-02-18 08:47 |
Oncoinvent ASA: Registration of new share capital
|
English | 2.1 KB | ||
| 2025-02-06 19:09 |
Oncoinvent ASA: Final results of the subsequent offering and allocation of offe…
|
English | 7.6 KB | ||
| 2025-02-06 07:00 |
Oncoinvent ASA: Last day of the subscription period in the subsequent offering
|
English | 5.9 KB | ||
| 2025-02-04 13:38 |
Oncoinvent ASA: Grant of share options - mandatory notification of trade
|
English | 260.4 KB |
Automate Your Workflow. Get a real-time feed of all Oncoinvent ASA filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Oncoinvent ASA
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Oncoinvent ASA via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
